CD3D Antibody

What is CD3D and why is it important in immunological research?

CD3D (CD3 delta) is a critical component of the T-cell receptor/CD3 complex (TCR/CD3 complex) present on the surface of T lymphocytes. It plays essential roles in both T-cell development and signal transduction. When antigen presenting cells (APCs) activate the T-cell receptor, CD3D along with other CD3 chains (CD3E, CD3G, and CD3Z) transmit signals across the cell membrane . All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domains that become phosphorylated by Src family protein tyrosine kinases upon TCR engagement .

Beyond signal transduction, CD3D is crucial for thymocyte differentiation by facilitating correct intracellular TCR-CD3 complex assembly and surface expression . CD3D also establishes functional links between the TCR and coreceptors CD4 and CD8, which is necessary for activation and positive selection of CD4 or CD8 T-cells . Understanding CD3D is vital for immunological research focusing on T cell development, activation, and immune response mechanisms.

What are the structural and biochemical properties of the CD3D protein?

The human CD3D protein consists of 171 amino acid residues with a molecular weight of approximately 18.9 kDa . Structurally, CD3D contains an extracellular immunoglobulin (Ig) domain and a single immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain .

Key biochemical characteristics include:

• Subcellular localization: Primarily in the cell membrane

• Tissue expression: Notably expressed in tonsil, thymus, and kidney

• Post-translational modifications: Undergoes phosphorylation and glycosylation

• Isoforms: Up to two different isoforms have been reported

In SDS-PAGE conditions, CD3D typically appears as a band at approximately 23 kDa, slightly higher than its predicted molecular weight due to post-translational modifications . The protein segment from Phe22 to Ala105 appears to be particularly important for antibody recognition in many commercial antibodies .

What are the common applications of CD3D antibodies in research settings?

CD3D antibodies are versatile tools employed in multiple research applications:

• Western Blot (WB): Detecting CD3D protein in cell lysates, typically revealing bands around 18-23 kDa . Recommended dilutions range from 1/500 to 1/2000 .

• Flow Cytometry (FCM/FACS): Identifying and quantifying T cells expressing CD3D on their surface, useful for immunophenotyping. Typical working dilutions are 1/200-1/400 .

• Immunohistochemistry (IHC): Visualizing CD3D expression in tissue sections, particularly in thymus and lymphoid tissues. CD3D is localized to cell surface and cytoplasm in lymphocytes .

• Immunocytochemistry (ICC): Detecting CD3D in cultured cells .

• Immunoprecipitation (IP): Isolating CD3D or CD3D-containing complexes for interaction studies .

• ELISA: Quantifying CD3D levels, with typical working dilutions around 1/10000 .

The CD3D marker is particularly valuable for identifying specific T cell subsets including CD4 Naïve Cells, CD4 Memory T Cells, Effector Memory CD45RA CD4 T Cells, CD8 Naïve Cells, and CD8 Effector Memory T Cells .

How should researchers validate CD3D antibodies before use in critical experiments?

Comprehensive validation of CD3D antibodies is essential before using them in critical experiments:

• Specificity testing: Use positive controls such as Jurkat human acute T cell leukemia cell line and negative controls like non-T cell lines (HL-60, U937) .

• Knockdown/knockout validation: Compare antibody reactivity in wild-type versus CD3D-knockdown cells. Studies have shown that CD3D knockdown in mature T cells leads to TCR ensembles that are retained in the endoplasmic reticulum .

• Peptide competition: Pre-incubate the antibody with the immunizing peptide (e.g., recombinant CD3D fragments) to confirm specific binding .

• Cross-reactivity assessment: Verify reactivity across species if cross-species applications are planned. Many CD3D antibodies are specific to human samples, while others may cross-react with mouse or rat CD3D .

• Application-specific validation:

  • For WB: Confirm expected band size (18-23 kDa) in appropriate controls

  • For IHC: Use human thymus as a positive control tissue

  • For flow cytometry: Verify staining patterns against established markers

• Batch consistency testing: When changing antibody lots, verify consistent performance across applications.

Proper validation ensures reliable experimental results and minimizes artifacts that could lead to misinterpretation of data.

What are the optimal conditions for using CD3D antibodies in Western blotting?

For optimal Western blot results with CD3D antibodies, consider the following protocol components:

• Sample preparation:

  • Use reducing conditions for optimal CD3D detection

  • Include protease inhibitors to prevent degradation

  • For T cell lines like Jurkat, direct lysis in SDS sample buffer works well

• Gel electrophoresis:

  • Use 12-15% gels for better resolution of the relatively small CD3D protein (18-23 kDa)

  • Load adequate protein (20-50 μg of total cell lysate is typically sufficient)

• Transfer conditions:

  • Transfer to PVDF membrane shows good results for CD3D detection

  • Semi-dry or wet transfer systems both work effectively

• Blocking and antibody incubation:

  • Block with 5% non-fat dry milk or BSA in TBST

  • Primary antibody dilutions typically range from 1/500 to 1/2000 or 2 μg/mL

  • Incubate primary antibody overnight at 4°C for optimal results

  • Use appropriate HRP-conjugated secondary antibody (e.g., Anti-Mouse IgG)

• Detection:

  • Use Western Blot Buffer Group 1 for consistent results

  • Enhanced chemiluminescence detection systems work well for CD3D visualization

A specific band for CD3D should be detected at approximately 23 kDa under reducing conditions . Multiple bands may indicate degradation products, different isoforms, or post-translational modifications.

How can researchers optimize CD3D antibody performance in immunohistochemical applications?

Optimizing CD3D antibody performance in immunohistochemistry requires attention to several key parameters:

• Tissue preparation:

  • Formalin-fixed, paraffin-embedded sections are suitable for CD3D detection

  • Optimal section thickness is typically 4-6 μm

• Antigen retrieval:

  • Heat-induced epitope retrieval is critical for CD3D detection

  • Use Antigen Retrieval Reagent-Basic for best results

  • Typical protocol: 95-100°C for 20 minutes in appropriate buffer

• Antibody concentration and incubation:

  • Start with 5 μg/mL for monoclonal CD3D antibodies

  • Incubate for 1 hour at room temperature or overnight at 4°C

  • Optimize by testing a range of concentrations (1-10 μg/mL)

• Detection system:

  • Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody provides sensitive detection

  • DAB (3,3'-diaminobenzidine) works well as a chromogen, producing brown staining

  • Counterstain with hematoxylin for contrast (blue nuclear staining)

• Controls:

  • Positive control: Human thymus shows robust CD3D expression

  • Negative control: Non-lymphoid tissues or primary antibody omission

• Expected results:

  • Specific staining should be localized to cell surface and cytoplasm in lymphocytes

  • Pattern should be consistent with known T cell distribution in the tissue

Following these guidelines should yield specific CD3D staining with minimal background, allowing accurate assessment of T cell distribution in tissues.

How do CD3D antibodies contribute to understanding T cell receptor complex assembly?

CD3D antibodies provide valuable insights into the complex process of TCR assembly:

• Structure and composition analysis:

  • The TCR/CD3 complex consists of variable TCR chains (either αβ or γδ) and several invariant dimers (CD3γε, CD3δε, and ζζ/CD247)

  • CD3D antibodies help determine how CD3δ associates with other components in this assembly

• Temporal sequence of assembly:

  • Using CD3D antibodies in pulse-chase experiments reveals when CD3δ joins the complex

  • Research shows that CD3D plays different roles in TCRαβ versus TCRγδ assembly

• Molecular requirements for stable complexes:

  • Studies using CD3D knockdown show that TCR ensembles lacking sufficient CD3D are retained in the endoplasmic reticulum, lack ζζ/CD247, and barely reach the cell surface (<11% of normal controls)

  • This indicates CD3D's critical role in complex transport and stability

• Differential requirements across T cell lineages:

  • Despite high sequence homology between CD3γ and CD3δ, studies show that CD3δ deficiency has more severe consequences than CD3γ deficiency

  • CD3D antibodies help determine why TCR ensembles are less stable when CD3γ is scarce compared to when CD3δ is reduced

Through these applications, CD3D antibodies contribute significantly to our understanding of the stepwise interactions among TCR chains during assembly and the specific requirements for functional TCR complex formation.

What insights have CD3D antibodies provided about immunodeficiencies caused by CD3D mutations?

CD3D antibodies have been instrumental in characterizing immunodeficiencies caused by CD3D mutations:

• Clinical phenotype characterization:

  • CD3D defects cause severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T-/B+/NK+ SCID)

  • CD3D antibodies help confirm the Tαβ−Tγδ+B+NK+ phenotype characteristic of this condition

• Molecular mechanism elucidation:

  • Studies using CD3D antibodies have revealed that even "leaky" mutations in CD3D differentially affect αβ and γδ T cells

  • Flow cytometry with CD3D antibodies showed that despite reduced αβ T cell numbers, TCR expression was approximately 2-fold lower in γδ than in αβ T cells from patients

• Functional consequences analysis:

  • CD3D antibodies helped demonstrate that early activation events such as CD69 or CD25 induction were strongly reduced in patients with CD3D mutations

  • While short-term proliferation remained intact, αβ T cells showed impaired long-term growth compared to γδ T cells

• Thymic development impact:

  • Analysis of recent thymic emigrants using CD3D antibodies indicated that patients' thymuses produced very few αβ T lymphocytes

These findings highlight the contrasting CD3δ requirements for αβ versus γδ T cell development and TCR expression in humans, emphasizing the diagnostic and clinical relevance of studying both TCR isotypes when a T cell defect is suspected .

How can CD3D antibodies be used to study CD3D phosphorylation during T cell activation?

Studying CD3D phosphorylation during T cell activation requires specialized approaches with CD3D antibodies:

• Experimental design considerations:

  • Use anti-CD3 stimulation to trigger TCR signaling cascades

  • Establish time-course experiments (seconds to minutes) to capture the dynamic nature of CD3D phosphorylation

  • Include proper inhibitors (phosphatase inhibitors) during cell lysis to preserve phosphorylation status

• Antibody selection strategy:

  • For total CD3D detection: Use standard CD3D antibodies that recognize the protein regardless of phosphorylation status

  • For phosphorylated forms: Use phospho-specific antibodies targeting the phosphorylated ITAM motifs

• Analytical techniques:

  • Western blotting: Sequential probing with phospho-specific and total CD3D antibodies

  • Flow cytometry: Intracellular staining for phosphorylated CD3D after fixation/permeabilization

  • Immunoprecipitation: Pull down with total CD3D antibodies followed by phospho-specific detection

• Controls and validation:

  • Positive controls: Anti-CD3 stimulated T cells at known peak phosphorylation times

  • Negative controls: Unstimulated cells or phosphatase-treated samples

  • Specificity validation: CD3D knockdown cells or competitive blocking with immunizing peptides

Through these approaches, researchers can track the phosphorylation kinetics of CD3D following T cell activation, providing valuable insights into early TCR signaling events and their regulation in normal and pathological conditions.

What are common technical challenges when using CD3D antibodies and their solutions?

When working with CD3D antibodies, researchers may encounter several technical challenges:

For Western blot specific issues, reducing conditions and appropriate buffer selection (Western Blot Buffer Group 1) have shown good results for CD3D detection . For flow cytometry, dilutions of 1/200-1/400 are typically effective for most commercial CD3D antibodies .

How should researchers interpret different staining patterns observed with various CD3D antibody clones?

Different CD3D antibody clones may produce varying staining patterns that require careful interpretation:

• Epitope-specific considerations:

  • Different clones target distinct regions of CD3D (e.g., AA 127-171, AA 22-105, or Phe22-Ala105)

  • Epitope accessibility may vary depending on TCR complex conformation or CD3D's association with other proteins

  • Post-translational modifications might mask certain epitopes

• Methodological factors affecting staining patterns:

  • Sample preparation techniques (fixation, permeabilization, denaturation) can differentially affect epitope exposure

  • Clone 1033614 works well in Western blot under reducing conditions and in IHC with heat-induced epitope retrieval

  • Clone 4B9G9 requires specific dilutions for different applications (1/500-1/2000 for WB, 1/200-1/400 for FCM)

• Interpretation framework:

  • Surface vs. intracellular staining: Some clones may preferentially detect surface CD3D while others detect total cellular CD3D

  • Differential staining between T cell subsets: Lower TCR expression in γδ versus αβ T cells has been observed in certain conditions

  • Staining intensity variations: May reflect biological differences in CD3D expression levels, accessibility, or complex formation

• Validation approach:

  • Use multiple antibody clones targeting different epitopes to obtain complementary information

  • Include appropriate positive controls (Jurkat cells) and negative controls

  • Correlate findings with functional data or orthogonal detection methods

Understanding these factors helps researchers select appropriate antibody clones for specific applications and correctly interpret seemingly discrepant results between different antibodies.

What considerations are important when using CD3D antibodies in multiplex immunofluorescence or multicolor flow cytometry?

When incorporating CD3D antibodies into multiplex assays, several critical factors must be addressed:

• Panel design considerations:

  • Fluorophore selection: Choose fluorophores for CD3D antibodies based on its expected expression level (bright fluorophores for low expression)

  • Spectral compatibility: Carefully select fluorophore combinations to minimize spectral overlap

  • CD3D typically works well in panels with other T cell markers (CD4, CD8, CD45RA/RO) for comprehensive T cell phenotyping

• Technical optimization:

  • Titration: Determine optimal concentrations for each antibody in the multiplex context, not just individually

  • Compensation: Properly compensate for spectral overlap using single-stained controls

  • Blocking strategy: Use robust blocking to prevent non-specific binding, especially important in multiplex settings

• Antibody compatibility testing:

  • Sequential vs. simultaneous staining: Determine if antibodies can be applied simultaneously or require sequential application

  • Antibody isotype considerations: Plan panels accounting for secondary antibody cross-reactivity if using indirect staining

  • Buffer compatibility: Ensure all antibodies perform optimally in the selected staining buffer

• Data analysis strategies:

  • Gating strategy: Develop consistent gating approaches accounting for differential CD3D expression in T cell subsets

  • Co-expression analysis: Utilize bivariate plots to examine co-expression of CD3D with other markers

  • Dimensionality reduction: Consider computational approaches (tSNE, UMAP) for high-parameter data visualization

• Controls specific to multiplex systems:

  • Fluorescence minus one (FMO) controls: Essential for setting boundaries between positive and negative populations

  • Biological controls: Include samples with known alterations in CD3D expression

  • Isotype controls: Particularly important when using multiple antibodies of the same isotype

Adhering to these guidelines ensures reliable results when incorporating CD3D antibodies into complex multiparameter experimental systems.

How are CD3D antibodies being utilized in single-cell analysis technologies?

CD3D antibodies are finding important applications in cutting-edge single-cell technologies:

• Single-cell RNA sequencing (scRNA-seq) integration:

  • CITE-seq (Cellular Indexing of Transcriptomes and Epitopes by Sequencing) utilizes oligonucleotide-tagged CD3D antibodies to simultaneously measure surface protein expression and transcriptomes

  • This approach allows correlation between CD3D protein levels and gene expression programs in individual T cells

  • Particularly valuable for identifying rare T cell subsets with unique CD3D expression patterns

• Mass cytometry (CyTOF) applications:

  • Metal-conjugated CD3D antibodies enable inclusion in highly multiplexed panels (40+ parameters)

  • Allows precise quantification of CD3D alongside numerous other markers to define detailed T cell phenotypes

  • Essential for comprehensive immune profiling in health and disease

• Imaging mass cytometry and multiplexed ion beam imaging:

  • Metal-labeled CD3D antibodies enable spatial analysis of T cells in tissue contexts

  • Provides insights into T cell localization relative to other cell types in tissues

  • Preserves spatial information that is lost in dissociated cell analyses

• Single-cell Western blotting:

  • Allows analysis of CD3D protein expression variation across individual cells

  • Can reveal heterogeneity in CD3D expression or phosphorylation not apparent in bulk analyses

• Microfluidic approaches:

  • CD3D antibodies in microfluidic systems enable T cell isolation and analysis at the single-cell level

  • Facilitates dynamic studies of CD3D behavior during T cell activation

These technologies are transforming our understanding of T cell heterogeneity and CD3D's role in diverse T cell subsets and states.

What role do CD3D antibodies play in studying TCR complex organization using super-resolution microscopy?

Super-resolution microscopy combined with CD3D antibodies has revolutionized our understanding of TCR complex organization:

• Nanoscale TCR cluster analysis:

  • CD3D antibodies labeled with appropriate fluorophores for super-resolution techniques (PALM, STORM, STED) enable visualization of TCR nanoclusters

  • These studies reveal that TCRs are not uniformly distributed but organized in nanoscale clusters on the T cell surface

  • CD3D labeling helps determine how different components of the TCR complex are arranged within these clusters

• Conformational changes during activation:

  • Super-resolution approaches with CD3D antibodies can detect conformational changes in the TCR complex upon ligand binding

  • By targeting different epitopes of CD3D with distinct fluorophores, researchers can measure distance changes using techniques like FRET

  • This provides insights into how signal is transmitted across the membrane following TCR engagement

• Methodological considerations:

  • Direct labeling of primary antibodies or use of smaller probes (Fab fragments, nanobodies) improves spatial resolution

  • Live-cell compatible super-resolution techniques allow dynamic analysis of CD3D behavior during T cell activation

  • Multi-color super-resolution approaches enable simultaneous visualization of CD3D with other TCR components or signaling molecules

• Correlative approaches:

  • Combining super-resolution microscopy of CD3D with functional readouts (calcium flux, phosphorylation) links structural organization to function

  • Correlative light and electron microscopy with CD3D labeling connects protein distribution to cellular ultrastructure

These advanced imaging approaches with CD3D antibodies are providing unprecedented insights into the nanoscale organization and dynamics of the TCR complex.

How can CD3D antibodies contribute to therapeutic monitoring in immunotherapy and transplantation?

CD3D antibodies serve important functions in monitoring therapeutic interventions affecting T cells:

• CAR-T cell therapy monitoring:

  • CD3D antibodies help track endogenous versus engineered T cells

  • Flow cytometry with CD3D antibodies enables quantification of CAR-T cell persistence and expansion

  • Changes in CD3D expression may indicate T cell exhaustion or activation states

• Transplantation monitoring:

  • CD3D antibodies assess T cell reconstitution following stem cell transplantation

  • Monitoring CD3D+ T cell subsets helps evaluate immune reconstitution kinetics

  • Particularly valuable in CD3D-deficient SCID patients receiving treatment, where reconstitution of normal CD3D expression indicates successful therapy

• Immunosuppressive therapy assessment:

  • CD3D antibodies help evaluate the impact of immunosuppressive drugs on T cell numbers and function

  • Quantitative flow cytometry using calibrated CD3D antibodies can measure absolute T cell numbers

  • Changes in CD3D expression may serve as biomarkers for rejection risk or over-immunosuppression

• Checkpoint inhibitor therapy:

  • CD3D antibodies in multiparameter flow panels help characterize T cell responses to checkpoint inhibitors

  • Changes in CD3D expression or T cell subset distribution may correlate with treatment response

  • Serial monitoring using standardized CD3D antibody panels provides longitudinal assessment

• Technical considerations for therapeutic monitoring:

  • Standardized protocols for consistent results across time points

  • Use of quantitative flow cytometry (with quantification beads) for absolute cell counts

  • Integration with functional assays to correlate CD3D expression with T cell functionality

These applications demonstrate how CD3D antibodies contribute not only to basic research but also to clinical monitoring and precision medicine approaches in immunotherapy and transplantation.